Ritu Baral
Stock Analyst at TD Cowen
(1.21)
# 3,542
Out of 4,944 analysts
31
Total ratings
37.04%
Success rate
-5.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Initiates: Buy | $76 | $48.63 | +56.28% | 1 | Aug 4, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Buy | $44 | $42.35 | +3.90% | 1 | Feb 5, 2025 | |
| SPRO Spero Therapeutics | Downgrades: Hold | n/a | $1.97 | - | 4 | Nov 18, 2024 | |
| ANTX AN2 Therapeutics | Downgrades: Hold | n/a | $1.05 | - | 2 | Nov 18, 2024 | |
| RNA Avidity Biosciences | Maintains: Buy | $56 → $78 | $45.84 | +70.16% | 1 | Oct 21, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $282 → $371 | $436.52 | -15.01% | 4 | Oct 21, 2024 | |
| INSM Insmed | Maintains: Buy | $75 → $98 | $126.53 | -22.55% | 3 | Aug 9, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $349 → $390 | $374.00 | +4.28% | 1 | Mar 15, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | n/a | $9.39 | - | 1 | Aug 8, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $125 → $175 | $20.40 | +757.84% | 1 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $21 | $24.65 | -14.81% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.51 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.97 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.89 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $21.62 | - | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.58 | - | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.57 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.60 | - | 2 | Jul 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $755.14 | - | 2 | Jan 12, 2018 |
Akero Therapeutics
Aug 4, 2025
Initiates: Buy
Price Target: $76
Current: $48.63
Upside: +56.28%
Palvella Therapeutics
Feb 5, 2025
Initiates: Buy
Price Target: $44
Current: $42.35
Upside: +3.90%
Spero Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.97
Upside: -
AN2 Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.05
Upside: -
Avidity Biosciences
Oct 21, 2024
Maintains: Buy
Price Target: $56 → $78
Current: $45.84
Upside: +70.16%
Alnylam Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $436.52
Upside: -15.01%
Insmed
Aug 9, 2024
Maintains: Buy
Price Target: $75 → $98
Current: $126.53
Upside: -22.55%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Outperform
Price Target: $349 → $390
Current: $374.00
Upside: +4.28%
Sagimet Biosciences
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $9.39
Upside: -
Sarepta Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $20.40
Upside: +757.84%
Aug 8, 2022
Maintains: Outperform
Price Target: $32 → $21
Current: $24.65
Upside: -14.81%
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.51
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $12.97
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.89
Upside: -
Jun 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $21.62
Upside: -
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.58
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.57
Upside: -
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $0.60
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $755.14
Upside: -